Posted by Michael Wonder on 03 Mar 2023
Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer
1 March 2023 - Approval is based on Phase 3 ARASENS trial data.
The European Commission has granted marketing authorisation in the European Union for Nubeqa (darolutamide), an oral androgen receptor inhibitor, plus androgen deprivation therapy in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer.
